Global practices of meningococcal vaccine use and impact on invasive disease
A number of countries now include meningococcal vaccines in their routine immunization programs. This review focuses on different approaches to including meningococcal vaccines in country programs across the world and their effect on the burden of invasive meningococcal disease (IMD) as reflected by...
Main Authors: | , , , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Maney Publishing
2014
|
Subjects: | |
Online Access: | http://hdl.handle.net/1959.13/1305552 |
id |
ftunivnewcastnsw:uon:21072 |
---|---|
record_format |
openpolar |
spelling |
ftunivnewcastnsw:uon:21072 2023-05-15T16:50:25+02:00 Global practices of meningococcal vaccine use and impact on invasive disease Ali, Asad Jafri, Rabab Zehra Zhujun, Shao Bhutta, Zulfiqar Abramson, Jon Messonnier, Nancy Tevi-Benissan, Carol Durrheim, David Eskola, Juhani Fermon, Florence Klugman, Keith P. Ramsay, Mary Sow, Samba The University of Newcastle. Faculty of Health & Medicine, School of Medicine and Public Health 2014 http://hdl.handle.net/1959.13/1305552 eng eng Maney Publishing Pathogens and Global Health Vol. 108, Issue 1, p. 11-20 10.1179/2047773214Y.0000000126 invasive meningococcal disease epidemiology vaccines immunization schedule meningococcemia serogroup global immunity meningococcus meningitis journal article 2014 ftunivnewcastnsw 2018-07-27T00:48:04Z A number of countries now include meningococcal vaccines in their routine immunization programs. This review focuses on different approaches to including meningococcal vaccines in country programs across the world and their effect on the burden of invasive meningococcal disease (IMD) as reflected by pre and post-vaccine incidence rates in the last 20 years. Mass campaigns using conjugated meningococcal vaccines have lead to control of serogroup C meningococcal disease in the UK, Canada, Australia, Spain, Belgium, Ireland, and Iceland. Serogroup B disease, predominant in New Zealand, has been dramatically decreased, partly due to the introduction of an outer membrane vesicle (OMV) vaccine. Polysaccharide vaccines were used in high risk people in Saudi Arabia and Syria and in routine immunization in China and Egypt. The highest incidence region of the meningitis belt initiated vaccination with the serogroup A conjugate vaccine in 2010 and catch-up vaccination is ongoing. Overall results of this vaccine introduction are encouraging especially in countries with a moderate to high level of endemic disease. Continued surveillance is required to monitor effectiveness in countries that recently implemented these programs. Article in Journal/Newspaper Iceland NOVA: The University of Newcastle Research Online (Australia) Canada New Zealand |
institution |
Open Polar |
collection |
NOVA: The University of Newcastle Research Online (Australia) |
op_collection_id |
ftunivnewcastnsw |
language |
English |
topic |
invasive meningococcal disease epidemiology vaccines immunization schedule meningococcemia serogroup global immunity meningococcus meningitis |
spellingShingle |
invasive meningococcal disease epidemiology vaccines immunization schedule meningococcemia serogroup global immunity meningococcus meningitis Ali, Asad Jafri, Rabab Zehra Zhujun, Shao Bhutta, Zulfiqar Abramson, Jon Messonnier, Nancy Tevi-Benissan, Carol Durrheim, David Eskola, Juhani Fermon, Florence Klugman, Keith P. Ramsay, Mary Sow, Samba Global practices of meningococcal vaccine use and impact on invasive disease |
topic_facet |
invasive meningococcal disease epidemiology vaccines immunization schedule meningococcemia serogroup global immunity meningococcus meningitis |
description |
A number of countries now include meningococcal vaccines in their routine immunization programs. This review focuses on different approaches to including meningococcal vaccines in country programs across the world and their effect on the burden of invasive meningococcal disease (IMD) as reflected by pre and post-vaccine incidence rates in the last 20 years. Mass campaigns using conjugated meningococcal vaccines have lead to control of serogroup C meningococcal disease in the UK, Canada, Australia, Spain, Belgium, Ireland, and Iceland. Serogroup B disease, predominant in New Zealand, has been dramatically decreased, partly due to the introduction of an outer membrane vesicle (OMV) vaccine. Polysaccharide vaccines were used in high risk people in Saudi Arabia and Syria and in routine immunization in China and Egypt. The highest incidence region of the meningitis belt initiated vaccination with the serogroup A conjugate vaccine in 2010 and catch-up vaccination is ongoing. Overall results of this vaccine introduction are encouraging especially in countries with a moderate to high level of endemic disease. Continued surveillance is required to monitor effectiveness in countries that recently implemented these programs. |
author2 |
The University of Newcastle. Faculty of Health & Medicine, School of Medicine and Public Health |
format |
Article in Journal/Newspaper |
author |
Ali, Asad Jafri, Rabab Zehra Zhujun, Shao Bhutta, Zulfiqar Abramson, Jon Messonnier, Nancy Tevi-Benissan, Carol Durrheim, David Eskola, Juhani Fermon, Florence Klugman, Keith P. Ramsay, Mary Sow, Samba |
author_facet |
Ali, Asad Jafri, Rabab Zehra Zhujun, Shao Bhutta, Zulfiqar Abramson, Jon Messonnier, Nancy Tevi-Benissan, Carol Durrheim, David Eskola, Juhani Fermon, Florence Klugman, Keith P. Ramsay, Mary Sow, Samba |
author_sort |
Ali, Asad |
title |
Global practices of meningococcal vaccine use and impact on invasive disease |
title_short |
Global practices of meningococcal vaccine use and impact on invasive disease |
title_full |
Global practices of meningococcal vaccine use and impact on invasive disease |
title_fullStr |
Global practices of meningococcal vaccine use and impact on invasive disease |
title_full_unstemmed |
Global practices of meningococcal vaccine use and impact on invasive disease |
title_sort |
global practices of meningococcal vaccine use and impact on invasive disease |
publisher |
Maney Publishing |
publishDate |
2014 |
url |
http://hdl.handle.net/1959.13/1305552 |
geographic |
Canada New Zealand |
geographic_facet |
Canada New Zealand |
genre |
Iceland |
genre_facet |
Iceland |
op_relation |
Pathogens and Global Health Vol. 108, Issue 1, p. 11-20 10.1179/2047773214Y.0000000126 |
_version_ |
1766040562643763200 |